Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

By Christy Santhosh May 30 (Reuters) - Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of ...

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...

A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) has uncovered a crucial biological "off switch" in diffuse large B cell ...

Researchers at the University of Southampton have identified a new subtype of lymphoma which could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer ...

Traits of noncancerous cells in diffuse large B-cell lymphoma (DLBCL) tumors appear to offer insight into which patients will benefit the most from chimeric antigen receptor (CAR) T-cell therapy, ...

Two-year follow up from Arm 8 of the EPCORE NHL-2 trial (abstract 64) showed fixed-duration epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone ...

The risk for central nervous system (CNS) involvement is small in cases of diffuse large B-cell lymphoma (DLBCL) because only about 5% of patients develop it. But certain high-risk patients are even ...

Incyte (INCY) stock is in focus as Xencor (XNCR)-partnered lymphoma drug Monjuvi, as part of a combination regimen, lifts cancer-free survival by 25%. Read more here.